| 13.21 0.095 (0.72%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.57 | 1-year : | 17.37 |
| Resists | First : | 14.18 | Second : | 14.87 |
| Pivot price | 13.8  |
|||
| Supports | First : | 13.07 | Second : | 10.88 |
| MAs | MA(5) : | 13.38 |
MA(20) : | 13.93 |
| MA(100) : | 15.26 |
MA(250) : | 16.76 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 11.2 |
D(3) : | 14.8 |
| RSI | RSI(14): 34.9  |
|||
| 52-week | High : | 20.29 | Low : | 13.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDWD ] has closed above bottom band by 12.6%. Bollinger Bands are 19.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.34 - 13.42 | 13.42 - 13.49 |
| Low: | 12.89 - 12.99 | 12.99 - 13.08 |
| Close: | 13.07 - 13.21 | 13.21 - 13.34 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Sun, 16 Aug 2026
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Fri, 14 Aug 2026
Key facts: MediWound Ltd. (MDWD) Q2 $3.09M rev; EscharEx $4B target - TradingView
Fri, 14 Aug 2026
MediWound (MDWD) Stock Faces Cash Burn As Revenue Slips - Sahm
Thu, 13 Aug 2026
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record - GuruFocus
Thu, 13 Aug 2026
MediWound: Q2 Earnings Snapshot - KTVB
Thu, 13 Aug 2026
MediWound (NASDAQ: MDWD) revenue drops in H1 2026 but guidance held - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 16 (%) |
| Held by Institutions | 56.6 (%) |
| Shares Short | 1,620 (K) |
| Shares Short P.Month | 1,690 (K) |
| EPS | -2.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.22 |
| Profit Margin | -180.4 % |
| Operating Margin | -541.1 % |
| Return on Assets (ttm) | -23.6 % |
| Return on Equity (ttm) | -71.9 % |
| Qtrly Rev. Growth | -62.8 % |
| Gross Profit (p.s.) | 0.22 |
| Sales Per Share | 1.12 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -5.85 |
| PEG Ratio | 0 |
| Price to Book value | 4.1 |
| Price to Sales | 11.72 |
| Price to Cash Flow | -9.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|